News Investors Nasdaq: LGND Home About Portfolio Summary Technologies Licensing Opportunities PRESS RELEASES Press Releases Investor Presentations IR Calendar Email Alerts All News 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Ligand Reports Third Quarter 2021 Financial Results November 9, 2021 Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company November 9, 2021 Ligand to Report Third Quarter Financial Results on November 9, 2021 October 26, 2021 Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™ October 21, 2021 Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma August 30, 2021 Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy August 16, 2021 Ligand Reports Second Quarter 2021 Financial Results July 29, 2021 Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 July 21, 2021 Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes July 19, 2021 Ligand to Report Second Quarter Financial Results on July 29, 2021 July 16, 2021 Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors July 14, 2021 GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement June 2, 2021 Ligand Reports First Quarter 2021 Financial Results May 3, 2021 Ligand to Report First Quarter Financial Results on May 3, 2021 April 22, 2021 Ligand Reports Fourth Quarter and Full Year 2020 Financial Results February 3, 2021 1 2 3 4 5 6 7 8 9 10 ...31 Next » Twitter © 2021 Ligand Pharmaceuticals Incorporated All Rights Reserved. Privacy Policy Disclaimer Sitemap